AFFiRiS GmbH alzheimer’s vaccine progress In the clinical phase I trial AFF001, AFFiRiS GmbH has recruited the 24 Alzheimer patients planned because of this trial more info . The trial aims to investigate the tolerability and safety of a forward thinking Alzheimer’s vaccine . In the trial, all patients have been vaccinated at least once and have up to now tolerated the vaccine extremely well. The treatment provides for four vaccinations administered at regular intervals and is because of be fully finished by this October. The vaccine’s tolerability may then become conclusively evaluated. So far the results indicate great tolerability because of this Alzheimer’s vaccine from AFFiRiS GmbH.
In endocrinology, we are in the process of reactivating a Stage 3 trial with our oral ghrelin agonist, AEZS-130, as a diagnostic check for adult growth hormone insufficiency.’ SOURCE AETERNA ZENTARIS INC.. AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S. AEterna Zentaris Inc. , a worldwide biopharmaceutical company focused on oncology and endocrine therapy, announced the termination of the agreement with sanofi-aventis U today.S. dated March 5, 2009 for the advancement, commercialization and licensing of cetrorelix in benign prostatic hyperplasia for the U.S.